NN (NNBR) 10-Q 7 May 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2021	May 03, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	000-23486
Entity Registrant Name	NN, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	62-1096725
Entity Address, Address Line One	6210 Ardrey Kell Road, Suite 600
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28277
City Area Code	980
Local Phone Number	264-4300
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	NNBR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		43,064,365
Entity Central Index Key	0000918541
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Net sales	$ 126,804	$ 116,213
Cost of sales (exclusive of depreciation and amortization shown separately below)	99,688	94,478
Selling, general, and administrative expense	14,575	16,160
Depreciation and amortization	11,568	11,357
Goodwill impairment	0	92,942
Other operating expense (income), net	(5)	5,126
Income (loss) from operations	978	(103,850)
Interest expense	2,024	3,807
Loss on extinguishment of debt and write-off of debt issuance costs	2,390	0
Derivative payments on interest rate swap	1,717	0
Loss on interest rate swap	2,033	0
Other expense (income), net	(122)	1,544
Loss from continuing operations before benefit for income taxes and share of net income (loss) from joint venture	(7,064)	(109,201)
Benefit for income taxes	756	1,395
Share of net income (loss) from joint venture	1,395	(271)
Loss from continuing operations	(4,913)	(108,077)
Loss from discontinued operations, net of tax (Note 2)	0	(140,114)
Net loss	(4,913)	(248,191)
Other comprehensive loss:
Foreign currency translation loss	(3,347)	(14,342)
Change in fair value, net of tax	0	(11,209)
Reclassification adjustment for losses included in net loss, net of tax	2,851	1,052
Other comprehensive loss	(496)	(24,499)
Comprehensive loss	$ (5,409)	$ (272,690)
Basic net loss per common share:
Loss from continuing operations per common share (in dollars per share)	$ (0.46)	$ (2.64)
Loss from discontinued operations per common share (in dollars per share)	0	(3.32)
Net loss per common share (in dollars per shares)	$ (0.46)	$ (5.96)
Weighted average common shares outstanding, basic (in shares)	42,672	42,111
Diluted net loss per common share:
Loss from continuing operations per common share (in dollars per share)	$ (0.46)	$ (2.64)
Loss from discontinued operations per common share (in dollars per share)	0	(3.32)
Net loss per common share (in dollars per share)	$ (0.46)	$ (5.96)
Weighted average common shares outstanding, diluted (in shares)	42,672	42,111

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 43,033	$ 48,138
Accounts receivable, net	90,545	84,615
Inventories	67,531	62,517
Income tax receivable	8,956	8,800
Other current assets	12,431	11,148
Total current assets	222,496	215,218
Property, plant and equipment, net	218,057	223,690
Operating lease right-of-use assets	49,545	50,264
Intangible assets, net	99,479	103,065
Investment in joint venture	28,207	26,983
Other non-current assets	4,532	5,742
Total assets	622,316	624,962
Current liabilities:
Accounts payable	43,232	37,435
Accrued salaries, wages and benefits	24,613	21,296
Income tax payable	3,376	3,557
Current maturities of long-term debt	4,844	4,885
Current portion of operating lease liabilities	4,963	4,797
Other current liabilities	17,042	31,261
Total current liabilities	98,070	103,231
Deferred tax liabilities	10,326	11,178
Long-term debt, net of current portion	151,551	79,025
Operating lease liabilities, net of current portion	54,780	55,053
Other non-current liabilities	25,976	17,237
Total liabilities	340,703	265,724
Commitments and contingencies (Note 11)
Common stock - $0.01 par value per share, 90,000 shares authorized, 42,686 and 43,049 shares issued and outstanding at December 31, 2020 and March 31, 2021, respectively	430	427
Additional paid-in capital	479,341	493,332
Accumulated deficit	(210,788)	(205,875)
Accumulated other comprehensive loss	(34,228)	(33,732)
Total stockholders’ equity	234,755	254,152
Total liabilities, preferred stock, and stockholders’ equity	622,316	624,962
Series D Preferred Stock
Current liabilities:
Perpetual and convertible preferred stock	46,858	0
Series B Preferred Stock
Current liabilities:
Perpetual and convertible preferred stock	$ 0	$ 105,086

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000,000	90,000,000
Common stock, shares issued (in shares)	43,049,000	42,686,000
Common stock, shares outstanding (in shares)	43,049,000	42,686,000
Series D Preferred Stock
Preferred stock, par value (in dollars per share)	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000
Preferred stock, shares outstanding (in shares)	65,000
Preferred stock, shares issued (in shares)	65,000
Perpetual and convertible preferred stock	$ 46,858	$ 0
Series B Preferred Stock
Preferred stock, par value (in dollars per share)		$ 0.01
Preferred stock, shares authorized (in shares)		100,000
Preferred stock, shares outstanding (in shares)		100,000
Preferred stock, shares issued (in shares)		100,000
Perpetual and convertible preferred stock	$ 0	$ 105,086

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional paid-in capital	Warrants	Accumulated deficit	Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2019		42,313,000
Beginning balance at Dec. 31, 2019	$ 353,277	$ 423	$ 501,615	$ 1,076	$ (105,283)	$ (44,554)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(248,191)				(248,191)
Dividends accrued for preferred stock	(2,951)		(2,951)
Share-based compensation expense (in shares)		452,000
Share-based compensation expense	1,296	$ 5	1,291
Restricted shares forgiven for taxes (in shares)		(8,000)
Restricted shares forgiven for taxes	(30)		(30)
Change in fair value of interest rate swap, net of tax	(11,209)					(11,209)
Reclassification of interest rate swap settlement to net income (loss), net of tax	1,052					1,052
Foreign currency translation loss	(14,342)					(14,342)
Ending balance (in shares) at Mar. 31, 2020		42,757,000
Ending balance at Mar. 31, 2020	78,902	$ 428	499,925	$ 1,076	(353,474)	(69,053)
Beginning balance (in shares) at Dec. 31, 2020		42,686,000
Beginning balance at Dec. 31, 2020	254,152	$ 427	493,332		(205,875)	(33,732)
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Net loss	(4,913)				(4,913)
Dividends accrued for preferred stock	(14,529)		(14,529)
Share-based compensation expense (in shares)		413,000
Share-based compensation expense	886	$ 4	882
Restricted shares forgiven for taxes (in shares)		(50,000)
Restricted shares forgiven for taxes	(345)	$ (1)	(344)
Change in fair value of interest rate swap, net of tax	0
Reclassification of interest rate swap settlement to net income (loss), net of tax	2,851					2,851
Foreign currency translation loss	(3,347)					(3,347)
Ending balance (in shares) at Mar. 31, 2021		43,049,000
Ending balance at Mar. 31, 2021	$ 234,755	$ 430	$ 479,341		$ (210,788)	$ (34,228)

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]
Change in fair value of interest rate swap, tax		$ 3,390
Reclassification of interest rate swap settlement, tax	$ 861	$ 318

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss		$ (4,913)	$ (248,191)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization of continuing operations		11,568	11,357
Depreciation and amortization of discontinued operations		0	11,827
Amortization of debt issuance costs		405	1,652
Goodwill impairment of continuing operations		0	92,942
Goodwill impairment of discontinued operations		0	146,757
Loss on extinguishment of debt and write-off of debt issuance costs		2,390	0
Total derivative loss, net of cash settlements		3,750	0
Share of net income (loss) from joint venture, net of cash dividends received		(1,395)	271
Compensation expense from issuance of share-based awards		886	1,296
Deferred income taxes		(1,605)	(3,923)
Other		(1,081)	614
Changes in operating assets and liabilities:
Accounts receivable		(6,684)	1,760
Inventories		(5,589)	(2,507)
Accounts payable		7,094	3,584
Income taxes receivable and payable, net		(344)	(12,676)
Other		3,402	5,461
Net cash provided by operating activities		7,884	10,224
Cash flows from investing activities
Acquisition of property, plant and equipment		(5,468)	(11,260)
Proceeds from sale of property, plant, and equipment		11	82
Cash settlements of interest rate swap		(15,420)	0
Net cash used in investing activities		(20,877)	(11,178)
Cash flows from financing activities
Cash paid for debt issuance costs		(6,856)	(286)
Proceeds from issuance of preferred stock		61,918	0
Redemption of preferred stock		(122,434)	0
Proceeds from long-term debt		150,000	60,012
Repayments of long-term debt		(70,721)	(4,527)
Repayments of short-term debt, net		(1,090)	(411)
Other		(1,189)	(888)
Net cash provided by financing activities		9,628	53,900
Effect of exchange rate changes on cash flows		(1,740)	(5,435)
Net change in cash and cash equivalents		(5,105)	47,511
Cash and cash equivalents at beginning of period	[1]	48,138	31,703
Cash cash equivalents at end of period	[1]	$ 43,033	$ 79,214
[1]	Cash and cash equivalents include $11.7 million and $13.8 million of cash and cash equivalents that were included in current assets of discontinued operations as of March 31, 2020, and December 31, 2019, respectively.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 11.7	$ 13.8

Interim Financial Statements

Interim Financial Statements	3 Months Ended
	Mar. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Interim Financial Statements Nature of Business NN, Inc. is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies primarily for the automotive, general industrial, electrical, aerospace and defense, and medical markets. As used in this Quarterly Report on Form 10-Q (this “Quarterly Report”), the terms “NN,” the “Company,” “we,” “our,” or “us” refer to NN, Inc., and its subsidiaries. Basis of Presentation The accompanying condensed consolidated financial statements have not been audited. The Condensed Consolidated Balance Sheet as of December 31, 2020, was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 15, 2021. Historical periods presented reflect reclassifications for discontinued operations (see Note 2). In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three months ended March 31, 2021 and 2020; financial position as of March 31, 2021, and December 31, 2020; and cash flows for the three months ended March 31, 2021 and 2020, on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards (see Accounting Standards Recently Adopted section below). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2020 Annual Report. The results for the three months ended March 31, 2021, are not necessarily indicative of results for the year ending December 31, 2021, or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands. Accounting Standards Recently Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, (“ASU 2019-12”) as part of its initiative to reduce complexity in accounting standards. ASU 2019-12 removes certain exceptions and provides simplification to specific tax items to improve consistent application. This standard was effective for us beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements and related disclosures. Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, (“ASU 2020-06”) which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, ASU 2020-06 simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. In addition, ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. Further, for the diluted earnings-per-share calculation, the new guidance requires entities to use the if-converted method for all convertible instruments and generally requires entities to include the effect of share settlement for instruments that may be settled in cash or shares, among other things. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. Either the full or modified retrospective adoption method is allowed. We are currently evaluating the impact on our consolidated financial statements and related disclosures.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations In October 2020, we closed on the sale of our Life Sciences business under the terms of a Stock Purchase Agreement (the “SPA”) with affiliates of American Securities LLC for $753.3 million cash. The SPA includes a potential earnout payment of up to $70 million based on the performance of the Life Sciences business during the year ending December 31, 2022, measured by Adjusted EBITDA targets, as defined by the SPA. After working capital and other closing adjustments, we received cash proceeds at closing of $757.2 million and have recorded a $3.9 million payable as of March 31, 2021, and December 31, 2020, for the balance. Under the terms of a transition services agreement, we provided certain support services after the sale. In accordance with the terms of the SPA, we agreed to indemnify the buyer for certain tax liabilities on its consolidated federal income tax return related to the Life Sciences business during the portion of the year ended December 31, 2020, prior to the change in ownership on October 6, 2020. We estimate that the tax indemnification will result in a payment of approximately $1.2 million to the buyer during the year ending December 31, 2021, and we have recorded this estimated obligation in the “Other current liabilities” line item on the Condensed Consolidated Balance Sheets as of March 31, 2021, and December 31, 2020. In accordance with ASC 205-20, Presentation of Financial Statements - Discontinued Operations , the operating results of the Life Sciences business are classified as discontinued operations. The presentation of discontinued operations includes revenues and expenses of the discontinued operations as well as any gain on the disposition of the business, all net of tax, as one line item on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for all historical periods presented have been revised to reflect this presentation. Accordingly, the results of the Life Sciences business have been excluded from continuing operations and segment results for all historical periods presented in the condensed consolidated financial statements and the accompanying notes unless otherwise stated. The Condensed Consolidated Statements of Cash Flows for historical periods include cash flows of the Life Sciences business in each line item unless otherwise stated. The following table presents the operating results of the discontinued operations. Three Months Ended Net sales $ 83,532 Cost of sales (exclusive of depreciation and amortization shown separately below) 57,763 Selling, general, and administrative expense 8,405 Depreciation and amortization 11,827 Goodwill impairment 146,757 Other operating expense, net 3 Loss from operations (141,223) Interest expense 13,270 Other income, net (424) Loss from discontinued operations before costs of disposal and benefit for income taxes (154,069) Benefit for income taxes 14,187 Loss from discontinued operations before costs of disposal (139,882) Costs of disposal of discontinued operations (1) (259) Benefit for income taxes on costs of disposal 27 Loss from discontinued operations, net of tax $ (140,114) _______________________________ (1) Represents incremental direct costs related to the sale of the Life Sciences business that were incurred prior to the closing of the sale. During the first quarter of 2020, our market capitalization declined to a level that was less than the net book value of our stockholders’ equity. The decline in market capitalization was a triggering event that caused us to perform a goodwill impairment analysis as of March 31, 2020. The carrying value of the Life Sciences reporting unit exceeded its estimated fair value as of March 31, 2020. As a result of our analysis, we recorded an impairment loss on goodwill of $146.8 million for Life Sciences. The judgments, assumptions, and estimates involved in the goodwill impairment analysis for the Life Sciences reporting unit are consistent with those discussed in Note 5. Our previous credit facility, which was in place at the time, required us to use proceeds from the sale of the Life Sciences business to prepay a portion of our previous debt. We paid $700 million in the aggregate on our term loans immediately after the transaction closed on October 6, 2020. The prepayment was applied to debt in accordance with the prepayment provisions of the previous credit agreement which was in place at the time. Average quarterly interest rates were multiplied by the required prepayment amounts to calculate interest expense to be reclassified to discontinued operations for historical periods presented. The following table summarizes the amount of interest expense related to the previous credit facility that has been reclassified to discontinued operations. Three Months Ended Interest on debt $ 12,136 Amortization of debt issuance costs 1,226 Capitalized interest and other (223) Other 131 Total interest expense of discontinued operations $ 13,270 The following table presents the significant noncash items and cash paid for capital expenditures of discontinued operations for each historical period presented. Three Months Ended Depreciation and amortization $ 11,827 Goodwill impairment 146,757 Amortization of debt issuance costs 1,226 Acquisition of property, plant and equipment 4,084 Right-of-use assets obtained in exchange for new finance lease liabilities 694

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information Our business is aggregated into the following two reportable segments: • Mobile Solutions, which is focused on growth in the automotive and general industrial end markets; and • Power Solutions, which is focused on growth in the electrical, general industrial, automotive, and aerospace and defense, and medical end markets. These divisions are considered our two operating segments as each engages in business activities for which it earns revenues and incurs expenses, discrete financial information is available for each, and this is the level at which the chief operating decision maker reviews discrete financial information for purposes of allocating resources and assessing performance. Historically, we had a third operating segment, Life Sciences, that was focused on growth in the medical end market. See Note 2 for information regarding the sale of the Life Sciences business on October 6, 2020. The results of the Life Sciences business are classified as discontinued operations for the three months ended March 31, 2020, and therefore are not included in the tabular presentation below. The following tables present results of continuing operations by reportable segment. Mobile Power Corporate Total Three Months Ended March 31, 2021 Net sales $ 77,776 $ 49,075 $ (47) (a) $ 126,804 Income (loss) from operations 6,090 2,432 (7,544) $ 978 Interest expense (2,024) Other (6,018) Loss from continuing operations before income taxes and share of net income from joint venture $ (7,064) Three Months Ended March 31, 2020 Net sales $ 69,884 $ 46,401 $ (72) (a) $ 116,213 Goodwill impairment — 92,942 — $ 92,942 Income (loss) from operations 264 (90,334) (13,780) $ (103,850) Interest expense (3,807) Other (1,544) Loss from continuing operations before income taxes and share of net loss from joint venture $ (109,201) _______________________________ (a) Includes elimination of intersegment transactions occurring during the ordinary course of business. As of March 31, 2021, and December 31, 2020, one customer represented 10% and 11%, respectively, of consolidated accounts receivable. Amounts due from this customer are primarily related to Mobile Solutions.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are comprised of the following amounts: March 31, 2021 December 31, 2020 Raw materials $ 23,605 $ 22,589 Work in process 22,626 20,758 Finished goods 21,300 19,170 Total inventories $ 67,531 $ 62,517

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill During the first quarter of 2020, our market capitalization declined to a level that was less than the net book value of our stockholders’ equity. The decline in market capitalization was a triggering event that caused us to perform a goodwill impairment analysis as of March 31, 2020. The goodwill impairment analysis required significant judgments to calculate the fair value for the Power Solutions reporting unit, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term growth rate for the operating segment, and determination of weighted average cost of capital. Our forecasts used in the goodwill impairment analysis reflected our expectations of declines in sales resulting from COVID-19. Significant assumptions and estimates are involved in the application of the discounted cash flow model to forecast operating cash flows, including market growth and market share, sales volumes and prices, costs to produce, discount rate, and estimated capital needs. Management considers historical experience and all available information at the time the fair values of its reporting units are estimated. Assumptions in estimating future cash flows are subject to a high degree of judgment and complexity. The carrying value of the Power Solutions reporting unit exceeded the estimated fair value as of the March 31, 2020, analysis. As a result of our analysis, we recorded an impairment loss on goodwill of $92.9 million to the “Goodwill impairment” line on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). As of March 31, 2021, and December 31, 2020, there was no remaining goodwill balance.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Intangible Assets, Net The following table shows changes in the carrying amount of intangible assets, net, by reportable segment. Mobile Power Total Balance as of December 31, 2020 $ 29,062 $ 74,003 $ 103,065 Amortization (838) (2,748) (3,586) Balance as of March 31, 2021 $ 28,224 $ 71,255 $ 99,479

Investment in Joint Venture

Investment in Joint Venture	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Investment in Joint Venture	Investment in Joint Venture We own a 49% investment in Wuxi Weifu Autocam Precision Machinery Company, Ltd. (the “JV”), a joint venture located in Wuxi, China. The JV is jointly controlled and managed, and we account for it under the equity method. The following table shows changes in our investment in the JV. Balance as of December 31, 2020 $ 26,983 Share of earnings 1,395 Foreign currency translation loss (171) Balance as of March 31, 2021 $ 28,207

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Our effective tax rate for continuing operations was 10.7% and 1.3% for the three months ended March 31, 2021 and 2020, respectively. The effective tax rate for the three months ended March 31, 2021, differs from the U.S. federal statutory tax rate of 21% primarily due to the accrual of tax on non-permanently reinvested unremitted earnings of foreign subsidiaries and by limitation on the amount of tax benefit recorded for loss carryforwards in certain jurisdictions where we believe it is more likely than not a portion of the future tax benefit may not be realized. In addition, the effective tax rate was unfavorably impacted by U.S. tax on the earnings of foreign subsidiaries under the global intangible low-taxed income (“GILTI”) regime. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted. The provisions of the legislation had a significant impact on the effective tax rate and income tax receivable of the Company for the three months ended March 31, 2020. Under the CARES Act, NOLs arising in tax years beginning after December 31, 2017, were carried back to preceding tax years when the federal tax rate was 35% rather than the currently enacted 21%. The effective tax rate for the three months ended March 31, 2020, was also adversely impacted by the non-deductible goodwill impairment recorded in that period, partially offset by impacts from the CARES Act.

Debt

Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Debt	Debt On March 22, 2021, we entered into a new $150.0 million term loan facility (the “Term Loan Facility”) and a new $50.0 million asset backed credit facility (the “ABL Facility”). The proceeds from the Term Loan Facility were used to prepay the amounts outstanding on our previous term loans. The previous credit facility was terminated and consisted of a Senior Secured Term Loan, Incremental Term Loan, and Senior Secured Revolver. No amounts were outstanding on the Senior Secured Revolver at the time of termination. The following table presents debt balances as of March 31, 2021, and December 31, 2020. March 31, 2021 December 31, 2020 Term Loan Facility $ 150,000 $ — Senior Secured Term Loan — 47,728 Incremental Term Loan — 22,716 International lines of credit and other loans 12,547 14,418 Total principal 162,547 84,862 Less-current maturities of long-term debt 4,844 4,885 Principal, net of current portion 157,703 79,977 Less-unamortized debt issuance costs (1) 6,152 952 Long-term debt, net of current portion $ 151,551 $ 79,025 _______________________________ (1) In addition to this amount, costs of $0.8 million related to the ABL Facility are recorded in other non-current assets as of March 31, 2021, and $1.8 million related to the Senior Secured Revolver are recorded in other non-current assets as of December 31, 2020. Term Loan Facility Outstanding borrowings under the Term Loan Facility bear interest at either 1) one-month LIBOR (subject to a 1.000% floor) plus an applicable margin of 6.875% or 2) the greater of various benchmark rates plus an applicable margin of 5.875%. At March 31, 2021, the Term Loan Facility bore interest based on one-month LIBOR at 7.875%. The Term Loan Facility requires quarterly principal payments of $0.4 million with the remaining unpaid principal amount due on the final maturity date of September 22, 2026. The Term Loan Facility is collateralized by all of our assets. The Term Loan Facility has a first lien on all assets other than accounts receivable and inventory and has a second lien on accounts receivable and inventory. We were in compliance with all requirements under the Term Loan Facility as of March 31, 2021. The Term Loan Facility was issued at a $3.8 million discount. We capitalized a total of $2.4 million in new debt issuance costs related to the Term Loan Facility. Debt issuance costs and original issue discount related to the Term Loan Facility are recorded as a direct reduction to the carrying amount of the associated long-term debt and amortized over the term of the debt. ABL Facility The ABL Facility provides for a senior secured revolving credit facility in the amount of $50.0 million, of which $30.0 million is available in the form of letters of credit and $5.0 million is available for the issuance of short-term swingline loans. The availability of credit under the ABL Facility is limited by a borrowing base calculation derived from accounts receivable and inventory held in the United States. Outstanding borrowings under the ABL Facility bear interest on a variable rate structure plus an interest rate spread that is based on the average amount of aggregate revolving commitment available. The variable borrowing rate is either 1) LIBOR plus an applicable margin of 1.75% or 2.00%, depending on availability, or 2) the greater of the federal funds rate or prime, plus an applicable margin of 0.75% or 1.00%, depending on availability. We may elect whether to use one-month, three-month, or six-month LIBOR, subject to a 0.50% floor. Interest payments are due monthly on borrowings that utilize one-month LIBOR and quarterly on borrowings that utilize three-month or six-month LIBOR. At March 31, 2021, using one-month LIBOR plus a 1.75% spread, the weighted average interest rate on outstanding borrowings under the ABL Facility would have been 2.25% if there had been any balance outstanding. We pay a commitment fee of 0.375% for unused capacity under the ABL Facility and a 0.125% fee on the amount of letters of credit outstanding. The final maturity date of the ABL Facility is March 22, 2026. We had no outstanding borrowings under the ABL Facility at March 31, 2021. Total capacity under the ABL Facility was $47.3 million as of March 31, 2021, with $32.9 million available for future borrowings after reductions for outstanding letters of credit as of March 31, 2021. The ABL Facility has a first lien on accounts receivable and inventory. We were in compliance with all requirements under the ABL Facility as of March 31, 2021. We capitalized a total of $0.8 million in new debt issuance costs related to the ABL Facility. Costs related to the ABL Facility are recorded in other non-current assets and amortized over the term of the agreement. Senior Secured Term Loan Outstanding borrowings under the Senior Secured Term Loan, bore interest at one-month LIBOR (subject to a 0.75% floor) plus an applicable margin of 5.75%. During 2021 until termination, the Senior Secured Term Loan bore interest at 6.50%. Incremental Term Loan Outstanding borrowings under the Incremental Term Loan bore interest at one-month LIBOR plus an applicable margin of 5.75%. During 2021 until termination, the Incremental Term Loan bore interest at 5.90%. Senior Secured Revolver Outstanding borrowings under the Senior Secured Revolver bore interest on a variable rate structure at either 1) one-month LIBOR plus an applicable margin of 4.00% or 2) the prime lending rate plus an applicable margin of 3.00%. We had no outstanding borrowings under the Senior Secured Revolver during 2021. We incurred a commitment fee of 0.50% for unused capacity under the Senior Secured Revolver until it was terminated. Debt Issuance Costs We recognized a $2.4 million loss on extinguishment for unamortized debt issuance costs that were written off in the three months ended March 31, 2021, in connection with the termination of our previous credit facility. Interest Rate Swap

Leases

Leases	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	Leases The following table contains supplemental cash flow information related to leases of continuing operations. Three Months Ended 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in finance leases $ 57 $ 61 Operating cash flows used in operating leases 4,103 3,348 Financing cash flows used in finance leases 846 580 Right-of-use assets obtained in exchange for new finance lease liabilities 60 710 Right-of-use assets obtained in exchange for new operating lease liabilities (1) — 13,241 _______________________________ (1) Includes new leases, renewals, and modifications.
Leases	Leases The following table contains supplemental cash flow information related to leases of continuing operations. Three Months Ended 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in finance leases $ 57 $ 61 Operating cash flows used in operating leases 4,103 3,348 Financing cash flows used in finance leases 846 580 Right-of-use assets obtained in exchange for new finance lease liabilities 60 710 Right-of-use assets obtained in exchange for new operating lease liabilities (1) — 13,241 _______________________________ (1) Includes new leases, renewals, and modifications.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Brazil ICMS Tax Matter Prior to the acquisition of Autocam Corporation in 2014 (“Autocam”), Autocam’s Brazilian subsidiary (“Autocam Brazil”) received notification from the Brazilian tax authority regarding ICMS (state value added tax or “VAT”) tax credits claimed on intermediary materials (e.g., tooling and perishable items) used in the manufacturing process. The Brazilian tax authority notification disallowed state ICMS tax credits claimed on intermediary materials based on the argument that these items are not intrinsically related to the manufacturing processes. Autocam Brazil filed an administrative defense with the Brazilian tax authority arguing, among other matters, that it should qualify for an ICMS tax credit, contending that the intermediary materials are directly related to the manufacturing process. We believe that we have substantial legal and factual defenses, and we plan to defend our interests in this matter vigorously. The matter encompasses several lawsuits filed with the Brazilian courts requesting declaratory actions that no tax is due or seeking a stay of execution on the collection of the tax. In 2018, we obtained a favorable decision in one of the declaratory actions for which the period for appeal has expired. We have filed actions in each court requesting dismissal of the matter based on the earlier court action. In May 2020, we received an unfavorable decision in one of the lawsuits, and as a result have recorded a liability to the Brazilian tax authorities and a receivable from the former shareholders of Autocam for the same amount. Although we anticipate a favorable resolution to the remaining matters, we can provide no assurances that we will be successful in achieving dismissal of all pending cases. The U.S. dollar amount that would be owed in the event of an unfavorable decision is subject to interest, penalties, and currency impacts and therefore is dependent on the timing of the decision. For the remaining open lawsuits, we currently believe the cumulative potential liability in the event of unfavorable decisions on all matters will be less than $5.0 million, inclusive of interest and penalties. We are entitled to indemnification from the former shareholders of Autocam, subject to the limitations and procedures set forth in the agreement and plan of merger relating to the Autocam acquisition. Management believes the indemnification would include amounts owed for the tax, interest, and penalties related to this matter. Accordingly, we don’t expect to incur a loss related to this matter even in the event of an unfavorable decision and, therefore, have not accrued an amount for the remaining matters as of March 31, 2021. Securities Offering Matter On November 1, 2019, Erie County Employees’ Retirement System, on behalf of a purported class of plaintiffs, filed a complaint in the Supreme Court of the State of New York, County of New York, against the Company, certain of the Company’s current and former officers and directors, and each of the underwriters involved in the Company’s public offering and sale of 14.4 million shares of its common stock pursuant to a preliminary prospectus supplement, dated September 10, 2018, a final prospectus supplement, dated September 13, 2018, and a base prospectus, dated April 19, 2017, relating to the Company’s effective shelf registration statement on Form S-3 (File No. 333-216737) (the “Offering”), which complaint was amended on January 24, 2020. The complaint alleges violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 in connection with the Offering. The plaintiffs seek to represent a class of stockholders who purchased shares of the Company’s common stock in the Offering. The complaint seeks unspecified monetary damages and other relief. The Company believes the complaint and allegations to be without merit and intends to vigorously defend itself against these actions. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on the Company’s financial position, results of operations, or cash flows. Other Legal Matters On October 26, 2020, Corre Opportunities Qualified Master Fund, LP, and Corre Horizon Fund, LP, filed a complaint in the Chancery Court of the State of Delaware against the Company. The complaint alleges that the Company’s sale of its Life Sciences business without obtaining the prior consent of the plaintiffs was a breach of the terms of the Series B Preferred Stock. The complaint seeks unspecified monetary damages and other relief. The Company believes the complaint and allegations to be without merit and intends to vigorously defend itself against these actions. The Company is unable at this time to determine whether the outcome of the litigation would have a material impact on the Company’s financial position, results of operations, or cash flows.

Preferred Stock and Stockholder

Preferred Stock and Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Temporary Equity Disclosure [Abstract]
Preferred Stock and Stockholders' Equity	Preferred Stock and Stockholders' Equity Series D Perpetual Preferred Stock On March 22, 2021, we completed a private placement of 65 thousand shares of newly designated Series D Perpetual Preferred Stock, with a par value of $0.01 per share (the “Series D Preferred Stock”) at a price of $1,000 per share, together with detachable warrants (the “2021 Warrants”) to purchase up to 1.9 million shares of our common stock at an exercise price of $0.01 per share. The Series D Preferred Stock has a liquidation preference of $1,000 per share and is redeemable at our option in cash, subject to the applicable redemption premium. Series D Preferred Stock shares earn cash dividends at a rate of 10.0% per year, payable quarterly in arrears, accruing whether or not earned or declared. If no cash dividend is paid, then the liquidation preference per share effective on the dividend date increases by 12.0% per year. On March 22, 2026, the cash dividend rate and in-kind dividend rate increase by 2.5% per year. Cash dividends are required beginning on September 30, 2027. The Series D Preferred Stock is classified as mezzanine equity, between liabilities and stockholders’ equity, because certain features of the Series D Preferred Stock could require redemption of the Series D Preferred Stock upon a change of control event that is considered not solely within our control. For initial recognition, the Series D Preferred Stock was recognized at a discounted value, net of issuance costs and allocation to warrants and a bifurcated embedded derivative. The aggregate discount is amortized as a deemed dividend through March 22, 2026, which is the date the dividend rate begins to increase by 2.5% per year. Deemed dividends adjust retained earnings (or in the absence of retained earnings, additional paid-in capital). In accordance with ASC 815-15, Derivatives and Hedging - Embedded Derivatives, certain features of the Series D Preferred Stock were bifurcated and accounted for as derivatives separately. Note 17 discusses the accounting for these features. As of March 31, 2021, the carrying value of the Series D Preferred Stock shares was $46.9 million which included $0.2 million of accumulated unpaid and deemed dividends. The following table presents the change in the Series D Preferred Stock carrying value during the three months ended March 31, 2021. Three Months Ended March 31, 2021 Beginning balance $ — Proceeds from issuance of shares, net of issuance costs 61,793 Fair value of 2021 Warrants issued (14,839) Recognition of bifurcated embedded derivative (282) Accrual of in-kind dividends 168 Amortization 18 Ending balance $ 46,858 Net cash proceeds of $61.8 million from the issuance of the Series D Preferred Stock, along with part of the proceeds from the Term Loan Credit Facility, were used to redeem all of the outstanding shares of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”). Series B Convertible Preferred Stock The Series B Preferred Stock had a liquidation preference of $1,000 per share and was redeemable in cash at our option, subject to the applicable redemption premium. Series B Preferred Stock shares earned cumulative dividends at a rate of 10.625% per year, and accrued whether or not earned or declared. The Series B Preferred Stock was recognized at a discounted value, net of issuance costs and allocation to warrants and bifurcated embedded derivatives. The aggregate discount was amortized as a deemed dividend through December 31, 2023, which is the date the holders had a non-contingent conversion option into a variable number of common shares equal to the liquidation preference plus accrued and unpaid dividends. Deemed dividends adjust retained earnings (or in the absence of retained earnings, additional paid-in capital). At redemption on March 22, 2021, the carrying value of the Series B Preferred Stock shares included $14.3 million of accumulated unpaid and deemed dividends. The following table presents the change in the Series B Preferred Stock carrying value during the three months ended March 31, 2021. Three Months Ended Beginning balance $ 105,086 Accrual of in-kind dividends 14,008 Amortization 335 Redemption (119,429) Ending balance $ — Preferred Share Purchase Rights

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Revenue from Contracts with Customers Revenue is recognized when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services. The company provides disaggregated revenue by geographical region and customer industry. Three Months Ended March 31, 2021 Mobile Power Intersegment Total United States and Puerto Rico $ 37,438 $ 39,806 $ (47) $ 77,197 China 14,414 1,506 — 15,920 Brazil 9,668 192 — 9,860 Mexico 5,015 3,397 — 8,412 Germany 1,767 164 — 1,931 Poland 1,180 4 — 1,184 Other 8,294 4,006 — 12,300 Total net sales $ 77,776 $ 49,075 $ (47) $ 126,804 Three Months Ended March 31, 2020 Mobile Power Intersegment Total United States and Puerto Rico $ 37,129 $ 38,297 $ (72) $ 75,354 China 7,692 1,157 — 8,849 Brazil 8,583 130 — 8,713 Mexico 4,836 2,143 — 6,979 Germany 2,150 39 — 2,189 Poland 1,758 5 — 1,763 Other 7,736 4,630 — 12,366 Total net sales $ 69,884 $ 46,401 $ (72) $ 116,213 Three Months Ended March 31, 2021 Mobile Power Intersegment Total Automotive $ 50,144 $ 13,460 $ 63,604 General Industrial 24,310 13,710 38,020 Electrical — 15,182 15,182 Other 3,322 6,723 (47) 9,998 Total net sales $ 77,776 $ 49,075 $ (47) $ 126,804 Three Months Ended March 31, 2020 Mobile Power Intersegment Total Automotive $ 49,074 $ 12,364 $ 61,438 General Industrial 17,979 12,543 30,522 Electrical — 13,861 13,861 Other 2,831 7,633 (72) 10,392 Total net sales $ 69,884 $ 46,401 $ (72) $ 116,213 Transaction Price Allocated to Future Performance Obligations We are required to disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 31, 2021, unless our contracts meet one of the practical expedients. Our contracts met the practical expedient for a performance obligation that is part of a contract that has an original expected duration of one year or less. Sales Concentration We recognized sales from a single customer of $13.1 million, or 10% of consolidated net sales, during the three months ended March 31, 2021. We recognized sales from another customer of $11.1 million, or 10% of consolidated net sales, during the three months ended March 31, 2020. Revenues from these customers are primarily in our Mobile Solutions segment.

Shared-Based Compensation

Shared-Based Compensation	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Shared-Based Compensation	Share-Based Compensation Share-based compensation cost is recognized in the “Selling, general, and administrative expense” line in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) except for $0.2 million, attributable to discontinued operations for the three months ended March 31, 2020. The following table lists the components of share-based compensation expense by type of award. Three Months Ended 2021 2020 Stock options $ 89 $ 181 Restricted stock 548 892 Performance share units 249 223 Share-based compensation expense $ 886 $ 1,296 Stock Options The following table presents stock option activity for the three months ended March 31, 2021. Number of Options Weighted- Weighted- Aggregate Outstanding at January 1, 2021 871 $ 12.41 Forfeited or expired (24) 13.41 Outstanding at March 31, 2021 847 $ 12.38 3.7 years $ — (1) Exercisable at March 31, 2021 751 $ 12.83 3.0 years $ — (1) _______________________________ (1) The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at March 31, 2021, was greater than the exercise price of any individual option grant. Restricted Stock During the three months ended March 31, 2021, we granted 425 thousand shares of restricted stock to non-executive directors, officers and certain other key employees. The shares of restricted stock granted during the three months ended March 31, 2021, vest pro-rata generally over three years for employees and over one year for non-executive directors. We determined the fair value of the shares awarded by using the closing price of our common stock as of the date of grant. The weighted average grant date fair value of restricted stock granted in the three months ended March 31, 2021, was $6.79 per share. Total grant date fair value of restricted stock that vested in the three months ended March 31, 2021, was $2.7 million. The following table presents the status of unvested restricted stock awards as of March 31, 2021, and changes during the three months then ended. Nonvested Weighted Unvested at January 1, 2021 385 $ 9.42 Granted 425 6.79 Vested (284) 9.50 Forfeited (12) 7.76 Unvested at March 31, 2021 514 $ 7.24 Performance Share Units Performance Share Units (“PSUs”) are a form of long-term incentive compensation awarded to executive officers and certain other key employees designed to directly align the interests of employees to the interests of our stockholders, and to create long-term stockholder value. PSUs granted in 2021 were made pursuant to the NN, Inc. 2019 Omnibus Incentive Plan and a Performance Share Unit Agreement (the “2019 Omnibus Agreement”). Some PSUs are based on total shareholder return (“TSR Awards”), and other PSUs are based on return on invested capital (“ROIC Awards”). The TSR Awards vest, if at all, upon our achieving a specified relative total shareholder return, which will be measured against the total shareholder return of the S&P SmallCap 600 Index during specified performance periods as defined in the 2019 Omnibus Agreement. The ROIC Awards vest, if at all, upon our achieving a specified average return on invested capital during the performance periods. Each performance period generally begins on January 1 of the year of grant and ends 36 months later on December 31. We recognize compensation expense over the performance period in which the performance and market conditions are measured. If the PSUs do not vest at the end of the performance periods, then the PSUs will expire automatically. Upon vesting, the PSUs will be settled by the issuance of shares of our common stock, subject to the award recipient’s continued employment. The actual number of shares of common stock to be issued to each award recipient at the end of the performance periods will be interpolated between a threshold and maximum payout amount based on actual performance results. No dividends will be paid on outstanding PSUs during the performance period; however, dividend equivalents will be paid based on the number of shares of common stock that are ultimately earned at the end of the performance periods. With respect to the TSR and ROIC Awards, a participant will earn 50% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” For performance levels falling between the values shown below, the percentages will be determined by interpolation. The following table presents the goals with respect to TSR Awards and ROIC Awards granted or modified in 2021. TSR Awards: Threshold Performance Target Performance Maximum Performance 2021 grants 35th Percentile 50th Percentile 75th Percentile ROIC Awards: Threshold Performance Target Performance Maximum Performance 2021 grants 6.3% 7.0% 8.6% 2020 grants (1) 6.7% 7.9% 8.7% _______________________________ (1) The performance levels for 2020 grants were modified by the compensation committee of the board of directors in the first quarter of 2021 to adjust for the sale of the Life Sciences business and the ongoing effects of the COVID-19 pandemic. We estimate the grant date fair value of TSR Awards using the Monte Carlo simulation model, as the total shareholder return metric is considered a market condition under ASC Topic 718, Compensation – stock compensation . The grant date fair value of ROIC Awards is based on the closing price of a share of our common stock on the date of grant. The following table presents the number of PSUs granted and the grant date fair value in the period presented. TSR Awards ROIC Awards Award Year Shares Grant Date Shares Grant Date Fair 2021 142 $8.58 172 $7.20 We recognize expense for ROIC Awards based on the probable outcome of the associated performance condition. We generally recognize an expense for ROIC Awards based on the Target Performance threshold of 100% because, at the date of grant, the Target Performance is the probable level of performance achievement. The following table presents the status of unvested PSUs as of March 31, 2021, and changes during the three months then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares Weighted Shares Weighted Nonvested at January 1, 2021 138 $ 10.58 160 $ 9.13 Granted 142 8.58 172 7.20 Nonvested at March 31, 2021 280 $ 9.56 332 $ 8.13

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income The following tables present the components of accumulated other comprehensive income (“AOCI”). Foreign Currency Translation Interest rate swap Income taxes (1) Total Balance at December 31, 2020 $ (30,881) $ (3,712) $ 861 $ (33,732) Other comprehensive income (loss) before reclassifications (3,347) — — (3,347) Amounts reclassified from AOCI to loss on interest rate swap (3) — 3,712 (861) 2,851 Net other comprehensive income (loss) (3,347) 3,712 (861) (496) Balance at March 31, 2021 $ (34,228) $ — $ — $ (34,228) Balance at December 31, 2019 $ (35,159) $ (12,234) $ 2,839 $ (44,554) Other comprehensive income (loss) before reclassifications (14,342) (14,599) 3,390 (25,551) Amounts reclassified from AOCI to interest expense (2) — 1,370 (318) 1,052 Net other comprehensive income (loss) (14,342) (13,229) 3,072 (24,499) Balance at March 31, 2020 $ (49,501) $ (25,463) $ 5,911 $ (69,053) _______________________ (1) Income tax effect of changes in interest rate swap. (2) Represents settlements on the interest rate swap while the hedge was effective. (3) Represents reclassification of derivative loss and settlements after discontinuation of hedge accounting.

Net Income (Loss) Per Common Sh

Net Income (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share In accordance with ASC 260, Earnings Per Share, a company that has participating securities is required to utilize the two-class method for calculating earnings per share (“EPS”) unless the treasury stock method results in lower EPS. The two-class method is an allocation of earnings between the holders of common stock and a company’s participating securities. Basic EPS is calculated by dividing income or loss attributable to common stockholders by the weighted average number of shares of common stock outstanding. To calculate diluted EPS, basic EPS is further adjusted to include the effect of potentially dilutive stock options, warrants, and convertible preferred stock. The following table summarizes the computation of basic and diluted net loss per common share. Three Months Ended 2021 2020 Numerator: Loss from continuing operations $ (4,913) $ (108,077) Less: Preferred stock cumulative dividends and deemed dividends (14,529) (2,951) Numerator for basic and diluted loss from continuing operations per common share (1) (19,442) (111,028) Loss from discontinued operations, net of tax (Note 2) — (140,114) Numerator for basic and diluted undistributed net loss per common share (1) $ (19,442) $ (251,142) Denominator: Weighted average common shares outstanding, basic and diluted 42,461 42,111 Weighted average warrants outstanding, basic and diluted (2) 211 — Shares used to calculate income (loss) per share, basic and diluted 42,672 42,111 Per common share net loss: Basic loss from continuing operations per common share $ (0.46) $ (2.64) Basic loss from discontinued operations per common share — (3.32) Basic net loss per common share $ (0.46) $ (5.96) Diluted loss from continuing operations per common share $ (0.46) $ (2.64) Diluted loss from discontinued operations per common share — (3.32) Diluted net loss per common share $ (0.46) $ (5.96) Cash dividends declared per common share $ — $ — _______________________________ (1) Preferred Stock does not participate in losses. (2) The 2021 Warrants are included in shares outstanding for calculation of basic earnings per share because they are exercisable with little to no consideration (see Note 17). The following table presents securities that could be potentially dilutive in the future that were excluded from the calculation of diluted net loss per common share because they had an anti-dilutive effect. Three Months Ended 2021 2020 Options 847 897 2019 Warrants 1,500 1,500 Preferred Stock, as-converted — 26,275 2,347 28,672

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is an exit price representing the expected amount that an entity would receive to sell an asset or pay to transfer a liability in an orderly transaction with market participants at the measurement date. We followed consistent methods and assumptions to estimate fair values as more fully described in the 2020 Annual Report. Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement. Our financial instruments that are subject to fair value disclosure consist of cash and cash equivalents, accounts receivable, accounts payable, derivatives, and long-term debt. As of March 31, 2021, the carrying values of these financial instruments approximated fair value. Derivative Financial Instruments Certain features were bifurcated and accounted for separately from the Series B Preferred Stock. The following features were recorded as derivatives. • Leverage ratio put feature. The Series B Preferred Stock included a redemption option based on a leverage ratio threshold that provided the preferred holder the option to convert the Series B Preferred Stock to a variable number of shares of common stock at a discount to the then fair value of our common stock. The conversion feature was considered a redemption right at a premium which was not clearly and closely related to the debt host. The conversion feature was terminated upon redemption of the Series B Preferred Stock in March 2021. • Dividends withholding. The Series B Preferred Stock bore a feature that could require us to make an effective distribution to purchasers which is indexed to the tax rate of the purchasers. This distribution would be partially offset by an adjustment to the redemption price and/or conversion rate. The dividends withholding feature was not clearly and closely related to the debt host. Upon redemption of the Series B Preferred Stock in March 2021, we made a net cash distribution of $3.0 million to settle this withholding feature after effectively receiving a $1.0 million offset from the purchasers upon redemption of the Series B Preferred Stock. • Warrants. The warrants issued with the Series B Preferred Stock (the “2019 Warrants”) are exercisable, in full or in part, at any time prior to December 11, 2026. The original exercise price was $12.00 per share, subject to anti-dilution adjustments in the event of future below market issuances, stock splits, stock dividends, combinations or similar events. The issuance of additional warrants with the Series D Preferred Stock in March 2021 resulted in an adjusted exercise price of $11.49 per share because the new warrants have an exercise price below market value. Certain features were bifurcated and accounted for separately from the Series D Preferred Stock that was issued on March 22, 2021. The following features were recorded as derivatives. • Change-in-control put feature. The Series D Preferred Stock includes a put feature that allows the holder to redeem the Series D Preferred Stock upon a change in control at the greater of 1) the liquidation preference plus accrued dividends or 2) 140% of the liquidation preference. The put feature is considered a redemption right at a premium and is not clearly and closely related to the debt host. • Warrants. The warrants issued with the Series D Preferred Stock (the “2021 Warrants”) are exercisable, in full or in part, at any time prior to March 22, 2027, at an exercise price of $0.01 per share, subject to anti-dilution adjustments in the event of certain future equity issuances, stock splits, stock dividends, combinations or similar events. The following tables show the liabilities measured at fair value for the above derivatives as of March 31, 2021, and December 31, 2020. Fair Value Measurements as of March 31, 2021 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ — Derivative liability - other non-current liabilities 13,414 — 1,370 Total $ 13,414 $ — $ 1,370 Fair Value Measurements as of December 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ 2,453 Derivative liability - other non-current liabilities — — 664 Total $ — $ — $ 3,117 The following table presents the change in the above derivatives during the three months ended March 31, 2021. Three Months Ended March 31, 2021 Beginning balance $ 3,117 Issuances 15,121 Change in fair value (1) (449) Settlements (3,005) Ending balance $ 14,784 _______________________________ (1) Changes in the fair value are recognized in the “Other expense (income), net” line in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). The fair value of the change-in-control put feature utilizes unobservable inputs based on the Company’s assessment of the probability of a change-in-control event occurring in a future period. The probability of a change-in-control event ranged from 1% to 10% as of March 31, 2021. The leverage ratio put feature, the dividends withholding feature, and the contingent dividends feature utilized unobservable inputs based on the best information available to determine the probability of the Series B Preferred Stock remaining outstanding for future periods. These inputs included probability assessments of how long the preferred stock would remain outstanding and whether the leverage ratio threshold would be exceeded. Inputs also included the percentage of Series B Preferred Stock held by non-U.S. resident holders and the applicable tax withholding rates for those holders. The probability of the Series B Preferred Stock remaining in future periods ranged from 3% to 2% as of December 31, 2020. The leverage ratio put feature also utilized unobservable inputs to determine the probability of the leverage ratio put being exercisable as of March 31, 2023, which ranged from 10% to 1% as of December 31, 2020. These probabilities were determined based on management’s assessment of facts and circumstances at each reporting date. An increase in these probabilities would result in an increase in the derivative liability fair value. Given the Series B Preferred Stock value changes by period as a result of dividends and redemption premiums, weighted average values for these assumptions are not meaningful. The fair value of the 2019 Warrants is determined using a valuation model, which utilizes unobservable inputs to determine the probability that the 2019 Warrants will remain outstanding for future periods. The probabilities resulted in a weighted average term of 4.3 years as of March 31, 2021, and 2.4 years as of December 31, 2020. The fair value of the 2021 Warrants is determined using the observable market price of a share of our common stock, less the $0.01 per share exercise price. Interest Rate Swap We manage our exposure to fluctuations in interest rates using a mix of fixed and variable rate debt. We had a fixed-rate interest rate swap agreement that changed the LIBOR-based portion of the interest rate on a portion of our variable rate debt to a fixed rate of 2.4575% (the “interest rate swap”). On March 22, 2021, we terminated the interest rate swap agreement with a $13.7 million cash payment in connection with the extinguishment of our previously outstanding long-term variable-rate debt. The interest rate swap was designated as a cash flow hedge at inception. However, in the fourth quarter of 2020, the interest rate swap no longer qualified as an effective hedge, and subsequent changes in fair value of the interest rate swap were recognized in earnings. Amounts recognized in earnings related to the interest rate swap are recorded in the “Loss on interest rate swap” line on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) except that cash settlements prior to termination are recognized in “Derivative payments on interest rate swap.” Cash settlements during 2021 are presented in investing activities on the Condensed Consolidated Statements of Cash Flows. The following table presents the effect of the interest rate swap on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Three Months Ended March 31, 2021 2020 Interest expense $ — $ 1,370 Derivative payments on interest rate swap 1,717 — Loss on interest rate swap 2,033 — The following table presents the liabilities measured at fair value on a recurring basis for the interest rate swap as of December 31, 2020. Fair Value Measurements as of December 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ 11,022 $ — Derivative liability - other non-current liabilities — 4,357 — Total $ — $ 15,379 $ — The inputs for determining fair value of the interest rate swap are classified as Level 2 inputs. Level 2 fair value is based on estimates using standard pricing models. These standard pricing models use inputs which are derived from or corroborated by observable market data such as interest rate yield curves, index forward curves, discount curves, and volatility surfaces. Counterparty to this derivative contract is a highly rated financial institution which we believe carries only a minimal risk of nonperformance. Fixed Rate Debt

Interim Financial Statements (P

Interim Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2021
Quarterly Financial Information Disclosure [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have not been audited. The Condensed Consolidated Balance Sheet as of December 31, 2020, was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020 (the “2020 Annual Report”), which we filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 15, 2021. Historical periods presented reflect reclassifications for discontinued operations (see Note 2). In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments necessary to fairly state our results of operations for the three months ended March 31, 2021 and 2020; financial position as of March 31, 2021, and December 31, 2020; and cash flows for the three months ended March 31, 2021 and 2020, on a basis consistent with our audited consolidated financial statements other than the adoption of new accounting standards (see Accounting Standards Recently Adopted section below). These adjustments are of a normal recurring nature and are, in the opinion of management, necessary to state fairly the Company’s financial position and operating results for the interim periods. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report. These unaudited condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and accompanying notes included in the 2020 Annual Report. The results for the three months ended March 31, 2021, are not necessarily indicative of results for the year ending December 31, 2021, or any other future periods. Except for per share data or as otherwise indicated, all U.S. dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands.
Accounting Standards Recently Adopted and Not Yet Adopted	Accounting Standards Recently Adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, (“ASU 2019-12”) as part of its initiative to reduce complexity in accounting standards. ASU 2019-12 removes certain exceptions and provides simplification to specific tax items to improve consistent application. This standard was effective for us beginning January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements and related disclosures. Accounting Standards Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, (“ASU 2020-06”) which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, ASU 2020-06 simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. In addition, ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exception. Further, for the diluted earnings-per-share calculation, the new guidance requires entities to use the if-converted method for all convertible instruments and generally requires entities to include the effect of share settlement for instruments that may be settled in cash or shares, among other things. ASU 2020-06 is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted. Either the full or modified retrospective adoption method is allowed. We are currently evaluating the impact on our consolidated financial statements and related disclosures.

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]
Summary of Discontinued Operations and Disposal Groups	The following table presents the operating results of the discontinued operations. Three Months Ended Net sales $ 83,532 Cost of sales (exclusive of depreciation and amortization shown separately below) 57,763 Selling, general, and administrative expense 8,405 Depreciation and amortization 11,827 Goodwill impairment 146,757 Other operating expense, net 3 Loss from operations (141,223) Interest expense 13,270 Other income, net (424) Loss from discontinued operations before costs of disposal and benefit for income taxes (154,069) Benefit for income taxes 14,187 Loss from discontinued operations before costs of disposal (139,882) Costs of disposal of discontinued operations (1) (259) Benefit for income taxes on costs of disposal 27 Loss from discontinued operations, net of tax $ (140,114) _______________________________ (1) Represents incremental direct costs related to the sale of the Life Sciences business that were incurred prior to the closing of the sale. Three Months Ended Interest on debt $ 12,136 Amortization of debt issuance costs 1,226 Capitalized interest and other (223) Other 131 Total interest expense of discontinued operations $ 13,270 The following table presents the significant noncash items and cash paid for capital expenditures of discontinued operations for each historical period presented. Three Months Ended Depreciation and amortization $ 11,827 Goodwill impairment 146,757 Amortization of debt issuance costs 1,226 Acquisition of property, plant and equipment 4,084 Right-of-use assets obtained in exchange for new finance lease liabilities 694

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Information	The following tables present results of continuing operations by reportable segment. Mobile Power Corporate Total Three Months Ended March 31, 2021 Net sales $ 77,776 $ 49,075 $ (47) (a) $ 126,804 Income (loss) from operations 6,090 2,432 (7,544) $ 978 Interest expense (2,024) Other (6,018) Loss from continuing operations before income taxes and share of net income from joint venture $ (7,064) Three Months Ended March 31, 2020 Net sales $ 69,884 $ 46,401 $ (72) (a) $ 116,213 Goodwill impairment — 92,942 — $ 92,942 Income (loss) from operations 264 (90,334) (13,780) $ (103,850) Interest expense (3,807) Other (1,544) Loss from continuing operations before income taxes and share of net loss from joint venture $ (109,201) _______________________________ (a) Includes elimination of intersegment transactions occurring during the ordinary course of business.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories are comprised of the following amounts: March 31, 2021 December 31, 2020 Raw materials $ 23,605 $ 22,589 Work in process 22,626 20,758 Finished goods 21,300 19,170 Total inventories $ 67,531 $ 62,517

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount of Intangible Assets Net	The following table shows changes in the carrying amount of intangible assets, net, by reportable segment. Mobile Power Total Balance as of December 31, 2020 $ 29,062 $ 74,003 $ 103,065 Amortization (838) (2,748) (3,586) Balance as of March 31, 2021 $ 28,224 $ 71,255 $ 99,479

Investment in Joint Venture (Ta

Investment in Joint Venture (Tables)	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Summarized Activity Related to Investment in Joint Venture	The following table shows changes in our investment in the JV. Balance as of December 31, 2020 $ 26,983 Share of earnings 1,395 Foreign currency translation loss (171) Balance as of March 31, 2021 $ 28,207

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Summary of Debt	The following table presents debt balances as of March 31, 2021, and December 31, 2020. March 31, 2021 December 31, 2020 Term Loan Facility $ 150,000 $ — Senior Secured Term Loan — 47,728 Incremental Term Loan — 22,716 International lines of credit and other loans 12,547 14,418 Total principal 162,547 84,862 Less-current maturities of long-term debt 4,844 4,885 Principal, net of current portion 157,703 79,977 Less-unamortized debt issuance costs (1) 6,152 952 Long-term debt, net of current portion $ 151,551 $ 79,025 _______________________________ (1) In addition to this amount, costs of $0.8 million related to the ABL Facility are recorded in other non-current assets as of March 31, 2021, and $1.8 million related to the Senior Secured Revolver are recorded in other non-current assets as of December 31, 2020.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Lease, Cost	The following table contains supplemental cash flow information related to leases of continuing operations. Three Months Ended 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in finance leases $ 57 $ 61 Operating cash flows used in operating leases 4,103 3,348 Financing cash flows used in finance leases 846 580 Right-of-use assets obtained in exchange for new finance lease liabilities 60 710 Right-of-use assets obtained in exchange for new operating lease liabilities (1) — 13,241 _______________________________ (1) Includes new leases, renewals, and modifications.

Preferred Stock and Stockhold_2

Preferred Stock and Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Temporary Equity Disclosure [Abstract]
Temporary Equity	The following table presents the change in the Series D Preferred Stock carrying value during the three months ended March 31, 2021. Three Months Ended March 31, 2021 Beginning balance $ — Proceeds from issuance of shares, net of issuance costs 61,793 Fair value of 2021 Warrants issued (14,839) Recognition of bifurcated embedded derivative (282) Accrual of in-kind dividends 168 Amortization 18 Ending balance $ 46,858 Three Months Ended Beginning balance $ 105,086 Accrual of in-kind dividends 14,008 Amortization 335 Redemption (119,429) Ending balance $ —

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Summary of Revenue from Contracts with Customers	Three Months Ended March 31, 2021 Mobile Power Intersegment Total United States and Puerto Rico $ 37,438 $ 39,806 $ (47) $ 77,197 China 14,414 1,506 — 15,920 Brazil 9,668 192 — 9,860 Mexico 5,015 3,397 — 8,412 Germany 1,767 164 — 1,931 Poland 1,180 4 — 1,184 Other 8,294 4,006 — 12,300 Total net sales $ 77,776 $ 49,075 $ (47) $ 126,804 Three Months Ended March 31, 2020 Mobile Power Intersegment Total United States and Puerto Rico $ 37,129 $ 38,297 $ (72) $ 75,354 China 7,692 1,157 — 8,849 Brazil 8,583 130 — 8,713 Mexico 4,836 2,143 — 6,979 Germany 2,150 39 — 2,189 Poland 1,758 5 — 1,763 Other 7,736 4,630 — 12,366 Total net sales $ 69,884 $ 46,401 $ (72) $ 116,213 Three Months Ended March 31, 2021 Mobile Power Intersegment Total Automotive $ 50,144 $ 13,460 $ 63,604 General Industrial 24,310 13,710 38,020 Electrical — 15,182 15,182 Other 3,322 6,723 (47) 9,998 Total net sales $ 77,776 $ 49,075 $ (47) $ 126,804 Three Months Ended March 31, 2020 Mobile Power Intersegment Total Automotive $ 49,074 $ 12,364 $ 61,438 General Industrial 17,979 12,543 30,522 Electrical — 13,861 13,861 Other 2,831 7,633 (72) 10,392 Total net sales $ 69,884 $ 46,401 $ (72) $ 116,213

Shared-Based Compensation (Tabl

Shared-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
Components of Share-Based Compensation Expense by Type of Award	The following table lists the components of share-based compensation expense by type of award. Three Months Ended 2021 2020 Stock options $ 89 $ 181 Restricted stock 548 892 Performance share units 249 223 Share-based compensation expense $ 886 $ 1,296
Reconciliation of Option Activity	The following table presents stock option activity for the three months ended March 31, 2021. Number of Options Weighted- Weighted- Aggregate Outstanding at January 1, 2021 871 $ 12.41 Forfeited or expired (24) 13.41 Outstanding at March 31, 2021 847 $ 12.38 3.7 years $ — (1) Exercisable at March 31, 2021 751 $ 12.83 3.0 years $ — (1) _______________________________ (1) The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at March 31, 2021, was greater than the exercise price of any individual option grant.
Reconciliation of Restricted Stock Option Activity	The following table presents the status of unvested restricted stock awards as of March 31, 2021, and changes during the three months then ended. Nonvested Weighted Unvested at January 1, 2021 385 $ 9.42 Granted 425 6.79 Vested (284) 9.50 Forfeited (12) 7.76 Unvested at March 31, 2021 514 $ 7.24
Schedule of Performance Based Awards Goals with Respect to TSR and ROIC	The following table presents the goals with respect to TSR Awards and ROIC Awards granted or modified in 2021. TSR Awards: Threshold Performance Target Performance Maximum Performance 2021 grants 35th Percentile 50th Percentile 75th Percentile ROIC Awards: Threshold Performance Target Performance Maximum Performance 2021 grants 6.3% 7.0% 8.6% 2020 grants (1) 6.7% 7.9% 8.7% _______________________________
Schedule of Number of Awards Granted and Grant Date Fair Value of Each Award in Periods	The following table presents the number of PSUs granted and the grant date fair value in the period presented. TSR Awards ROIC Awards Award Year Shares Grant Date Shares Grant Date Fair 2021 142 $8.58 172 $7.20
Summary of Status of Unvested PSU Awards	The following table presents the status of unvested PSUs as of March 31, 2021, and changes during the three months then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares Weighted Shares Weighted Nonvested at January 1, 2021 138 $ 10.58 160 $ 9.13 Granted 142 8.58 172 7.20 Nonvested at March 31, 2021 280 $ 9.56 332 $ 8.13

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income	The following tables present the components of accumulated other comprehensive income (“AOCI”). Foreign Currency Translation Interest rate swap Income taxes (1) Total Balance at December 31, 2020 $ (30,881) $ (3,712) $ 861 $ (33,732) Other comprehensive income (loss) before reclassifications (3,347) — — (3,347) Amounts reclassified from AOCI to loss on interest rate swap (3) — 3,712 (861) 2,851 Net other comprehensive income (loss) (3,347) 3,712 (861) (496) Balance at March 31, 2021 $ (34,228) $ — $ — $ (34,228) Balance at December 31, 2019 $ (35,159) $ (12,234) $ 2,839 $ (44,554) Other comprehensive income (loss) before reclassifications (14,342) (14,599) 3,390 (25,551) Amounts reclassified from AOCI to interest expense (2) — 1,370 (318) 1,052 Net other comprehensive income (loss) (14,342) (13,229) 3,072 (24,499) Balance at March 31, 2020 $ (49,501) $ (25,463) $ 5,911 $ (69,053) _______________________ (1) Income tax effect of changes in interest rate swap. (2) Represents settlements on the interest rate swap while the hedge was effective. (3) Represents reclassification of derivative loss and settlements after discontinuation of hedge accounting.

Net Income (Loss) Per Common _2

Net Income (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Summary of Net Income (Loss) Per Share	The following table summarizes the computation of basic and diluted net loss per common share. Three Months Ended 2021 2020 Numerator: Loss from continuing operations $ (4,913) $ (108,077) Less: Preferred stock cumulative dividends and deemed dividends (14,529) (2,951) Numerator for basic and diluted loss from continuing operations per common share (1) (19,442) (111,028) Loss from discontinued operations, net of tax (Note 2) — (140,114) Numerator for basic and diluted undistributed net loss per common share (1) $ (19,442) $ (251,142) Denominator: Weighted average common shares outstanding, basic and diluted 42,461 42,111 Weighted average warrants outstanding, basic and diluted (2) 211 — Shares used to calculate income (loss) per share, basic and diluted 42,672 42,111 Per common share net loss: Basic loss from continuing operations per common share $ (0.46) $ (2.64) Basic loss from discontinued operations per common share — (3.32) Basic net loss per common share $ (0.46) $ (5.96) Diluted loss from continuing operations per common share $ (0.46) $ (2.64) Diluted loss from discontinued operations per common share — (3.32) Diluted net loss per common share $ (0.46) $ (5.96) Cash dividends declared per common share $ — $ — _______________________________ (1) Preferred Stock does not participate in losses. (2) The 2021 Warrants are included in shares outstanding for calculation of basic earnings per share because they are exercisable with little to no consideration (see Note 17).
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table presents securities that could be potentially dilutive in the future that were excluded from the calculation of diluted net loss per common share because they had an anti-dilutive effect. Three Months Ended 2021 2020 Options 847 897 2019 Warrants 1,500 1,500 Preferred Stock, as-converted — 26,275 2,347 28,672

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Derivative Instruments	The following tables show the liabilities measured at fair value for the above derivatives as of March 31, 2021, and December 31, 2020. Fair Value Measurements as of March 31, 2021 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ — Derivative liability - other non-current liabilities 13,414 — 1,370 Total $ 13,414 $ — $ 1,370 Fair Value Measurements as of December 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ — $ 2,453 Derivative liability - other non-current liabilities — — 664 Total $ — $ — $ 3,117 The following table presents the change in the above derivatives during the three months ended March 31, 2021. Three Months Ended March 31, 2021 Beginning balance $ 3,117 Issuances 15,121 Change in fair value (1) (449) Settlements (3,005) Ending balance $ 14,784 _______________________________
Schedule of Interest Rate Derivatives	The following table presents the effect of the interest rate swap on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Three Months Ended March 31, 2021 2020 Interest expense $ — $ 1,370 Derivative payments on interest rate swap 1,717 — Loss on interest rate swap 2,033 —
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents the liabilities measured at fair value on a recurring basis for the interest rate swap as of December 31, 2020. Fair Value Measurements as of December 31, 2020 Description Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs Derivative liability - other current liabilities $ — $ 11,022 $ — Derivative liability - other non-current liabilities — 4,357 — Total $ — $ 15,379 $ —

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - USD ($) $ in Thousands	Oct. 06, 2020	Oct. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill impairment			$ 0	$ 92,942
Repayments of debt	$ 700,000
Life Sciences
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill impairment				$ 146,800
Discontinued Operations, Disposed of by Sale | Life Sciences
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate purchase price of the stock purchase plan		$ 753,300
Potential earnout payment		70,000
Proceeds from sale of business, net of cash sold		$ 757,200
Disposal group payables			3,900		$ 3,900
Estimated tax indemnification			$ 1,200		$ 1,200

Discontinued Operations - Summa

Discontinued Operations - Summary of Major Line Items Included in Results of Operations of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Goodwill impairment	$ 0	$ 146,757
Loss from discontinued operations, net of tax	$ 0	(140,114)
Discontinued Operations, Disposed of by Sale | Life Sciences
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales		83,532
Cost of sales (exclusive of depreciation and amortization shown separately below)		57,763
Selling, general, and administrative expense		8,405
Depreciation and amortization		11,827
Goodwill impairment		146,757
Other operating expense, net		3
Loss from operations		(141,223)
Interest expense		13,270
Other income, net		(424)
Loss from discontinued operations before costs of disposal and benefit for income taxes		(154,069)
Benefit for income taxes		14,187
Loss from discontinued operations before costs of disposal		(139,882)
Costs of disposal of discontinued operations		(259)
Benefit for income taxes on costs of disposal		27
Loss from discontinued operations, net of tax		$ (140,114)

Discontinued Operations - Inter

Discontinued Operations - Interest Expense Reclassified to Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of debt issuance costs	$ 405	$ 1,652
Total interest expense of discontinued operations	$ 2,024	3,807
Life Sciences | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest on debt		12,136
Amortization of debt issuance costs		1,226
Capitalized interest and other		(223)
Other		131
Total interest expense of discontinued operations		$ 13,270

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Significant Noncash Items and Cash Paid for Capital Expenditures of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization of discontinued operations	$ 0	$ 11,827
Goodwill impairment	0	146,757
Amortization of debt issuance costs	$ 405	1,652
Discontinued Operations, Disposed of by Sale | Life Sciences
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization of discontinued operations		11,827
Goodwill impairment		146,757
Amortization of debt issuance costs		1,226
Acquisition of property, plant and equipment		4,084
Right-of-use assets obtained in exchange for new finance lease liabilities		$ 694

Segment Information - Continuin

Segment Information - Continuing Operations by Reportable Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)segment	Mar. 31, 2020USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	2
Number of operating segments | segment	2
Segment Reporting Information [Line Items]
Net sales	$ 126,804	$ 116,213
Goodwill impairment	0	92,942
Income (loss) from operations	978	(103,850)
Interest expense	(2,024)	(3,807)
Other	(6,018)	(1,544)
Loss from continuing operations before benefit for income taxes and share of net income (loss) from joint venture	(7,064)	(109,201)
Operating Segments | Mobile Solutions
Segment Reporting Information [Line Items]
Net sales	77,776	69,884
Goodwill impairment		0
Income (loss) from operations	6,090	264
Operating Segments | Power Solutions
Segment Reporting Information [Line Items]
Net sales	49,075	46,401
Goodwill impairment		92,942
Income (loss) from operations	2,432	(90,334)
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net sales	(47)	(72)
Goodwill impairment		0
Income (loss) from operations	$ (7,544)	$ (13,780)

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Major Customer | Accounts receivable | Customer Concentration Risk
Revenue, Major Customer [Line Items]
Concentration risk, percentage	10.00%	11.00%

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 23,605	$ 22,589
Work in process	22,626	20,758
Finished goods	21,300	19,170
Inventories	$ 67,531	$ 62,517

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Goodwill [Line Items]
Goodwill impairment	$ 0	$ 92,942
Goodwill	$ 0		$ 0
Power Solutions
Goodwill [Line Items]
Goodwill impairment		$ 92,900

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	$ 103,065
Amortization	(3,586)
Ending balance	99,479
Mobile Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	29,062
Amortization	(838)
Ending balance	28,224
Power Solutions
Finite-lived Intangible Assets [Roll Forward]
Beginning Balance	74,003
Amortization	(2,748)
Ending balance	$ 71,255

Investment in Joint Venture - A

Investment in Joint Venture - Additional Information (Detail)	Mar. 31, 2021
Wuxi Weifu Autocam Precision Machinery Company, Ltd.
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%

Investment in Joint Venture - S

Investment in Joint Venture - Summarized Activity Related to Investment in Joint Venture (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity Method Investments [Roll Forward]
Beginning Balance	$ 26,983
Share of earnings	1,395	$ (271)
Ending Balance	28,207
Joint Venture
Equity Method Investments [Roll Forward]
Beginning Balance	26,983
Share of earnings	1,395
Foreign currency translation loss	(171)
Ending Balance	$ 28,207

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate from continuing operations	10.70%	1.30%
Effective income tax rate reconciliation, at federal statutory income tax rate, percent	21.00%

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Mar. 22, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Debt Instrument [Line Items]
Debt issuance costs, line of credit arrangements, net		$ 800,000		$ 1,800,000
Unamortized debt issuance cost, written-off		2,400,000
Cash settlements for interest rate swaps		$ 15,420,000	$ 0
Interest Rate Swap
Debt Instrument [Line Items]
Cash settlements for interest rate swaps	$ 13,700,000
Term Loan Facility
Debt Instrument [Line Items]
Borrowings	$ 150,000,000
Interest rate during period		7.875%
Principal payment amount		$ 400,000
Issuance discount		3,800,000
Debt issuance costs		2,400,000
Outstanding borrowings		$ 150,000,000		0
Term Loan Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin	6.875%
Term Loan Facility | London Interbank Offered Rate (LIBOR) | Minimum
Debt Instrument [Line Items]
Applicable margin	1.00%
Term Loan Facility | Various Benchmark Rates
Debt Instrument [Line Items]
Applicable margin	5.875%
ABL Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000,000
Interest rate during period		2.25%
Debt instrument, LIBOR floor rate	0.50%
Unused capacity, commitment fee percentage		0.375%
Outstanding borrowings		$ 0
Available capacity		47,300,000
Remaining borrowing capacity		32,900,000
Debt issuance costs, line of credit arrangements, net		$ 800,000
ABL Facility | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		1.75%
ABL Facility | London Interbank Offered Rate (LIBOR) | Maximum
Debt Instrument [Line Items]
Applicable margin	2.00%
ABL Facility | Federal Funds Or Prime Rate | Minimum
Debt Instrument [Line Items]
Applicable margin	0.75%
ABL Facility | Federal Funds Or Prime Rate | Maximum
Debt Instrument [Line Items]
Applicable margin	1.00%
Senior Secured Term Loan
Debt Instrument [Line Items]
Interest rate during period		6.50%
Debt instrument, LIBOR floor rate		0.75%
Outstanding borrowings		$ 0		47,728,000
Senior Secured Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		5.75%
Incremental Term Loan
Debt Instrument [Line Items]
Interest rate during period		5.90%
Outstanding borrowings		$ 0		$ 22,716,000
Incremental Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		5.75%
Senior Secured Revolver
Debt Instrument [Line Items]
Unused capacity, commitment fee percentage		0.50%
Minimum required cash proceeds		$ 0
Senior Secured Revolver | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Applicable margin		4.00%
Senior Secured Revolver | Prime Rate
Debt Instrument [Line Items]
Applicable margin		3.00%
Letters of credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 30,000,000
Unused capacity, commitment fee percentage		0.125%
Swingline loans
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 5,000,000

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
International lines of credit and other loans	$ 12,500	$ 14,400
Total principal	162,547	84,862
Less-current maturities of long-term debt	4,844	4,885
Principal, net of current portion	157,703	79,977
Less-unamortized debt issuance costs	6,152	952
Long-term debt, net of current portion	151,551	79,025
Debt issuance costs, line of credit arrangements, net	800	1,800
Term Loan Facility
Debt Instrument [Line Items]
Term loans	150,000	0
Senior Secured Term Loan
Debt Instrument [Line Items]
Term loans	0	47,728
Incremental Term Loan
Debt Instrument [Line Items]
Term loans	0	22,716
Foreign Line of Credit
Debt Instrument [Line Items]
International lines of credit and other loans	$ 12,547	$ 14,418

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in finance leases	$ 57	$ 61
Operating cash flows used in operating leases	4,103	3,348
Financing cash flows used in finance leases	846	580
Right-of-use assets obtained in exchange for new finance lease liabilities	60	710
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 0	$ 13,241

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	1 Months Ended
	Mar. 31, 2020USD ($)
Leases [Abstract]
Increase (decrease) in operating lease, right-of-use asset	$ (8.1)
Decrease in operating lease, liability, noncurrent	10.5
Decrease in operating lease, liability, current	0.6
Increase (decrease) in change between operating lease right-of-use assets and operating lease, liabilities	3
Loss on termination of lease	4.4
Impairment charge on termination of lease	$ 2.9

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) shares in Millions, $ in Millions	Nov. 01, 2019	Mar. 31, 2021
Loss Contingencies [Line Items]
Stock issued during period, shares, new issues (in shares)	14.4
Maximum
Loss Contingencies [Line Items]
Loss contingency, estimate of possible loss		$ 5

Preferred Stock and Stockhold_3

Preferred Stock and Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Mar. 22, 2026	Mar. 22, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Apr. 15, 2020
Temporary Equity [Line Items]
Accrual of in-kind dividends			$ 14,300
Proceeds from issuance of preferred stock			61,918	$ 0
Series C Junior Participating Preferred Stock | Common Stock
Temporary Equity [Line Items]
Purchase right, number of shares called by each right (in shares)						1
Series D Preferred Stock
Temporary Equity [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)		1,900,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 0.01
Temporary equity, liquidation preference per share (in dollars per share)		$ 1,000
Temporary equity, dividend rate, percentage		10.00%
Increase in dividend rate if no cash dividends paid		12.00%
Carrying value			46,858		$ 0
Accrual of in-kind dividends			$ 168
Proceeds from issuance of preferred stock		$ 61,800
Series D Preferred Stock | Forecast
Temporary Equity [Line Items]
Annual increase in dividend rate	2.50%
Series D Preferred Stock | Private Placement
Temporary Equity [Line Items]
Sale of stock, number of shares issued in transaction (in shares)		65,000
Temporary equity, par value (in dollars per share)		$ 0.01
Sale of stock, price per share (in dollars per share)		$ 1,000
Series B Preferred Stock
Temporary Equity [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 12
Temporary equity, liquidation preference per share (in dollars per share)			$ 1,000
Temporary equity, dividend rate, percentage			10.625%
Carrying value			$ 0		$ 105,086
Accrual of in-kind dividends			$ 14,008

Preferred Stock and Stockhold_4

Preferred Stock and Stockholders' Equity - Carrying Value Roll Forward (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Increase (Decrease) in Temporary Equity [Roll Forward]
Accrual of in-kind dividends	$ 14,300
Series D Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	0
Proceeds from issuance of shares, net of issuance costs	61,793
Fair value of 2021 Warrants issued	(14,839)
Recognition of bifurcated embedded derivative	(282)
Accrual of in-kind dividends	168
Amortization	18
Ending balance	46,858
Series B Preferred Stock
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	105,086
Accrual of in-kind dividends	14,008
Amortization	335
Redemption	(119,429)
Ending balance	$ 0

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Summary of Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue, Major Customer [Line Items]
Net sales	$ 126,804	$ 116,213
Automotive
Revenue, Major Customer [Line Items]
Net sales	63,604	61,438
General Industrial
Revenue, Major Customer [Line Items]
Net sales	38,020	30,522
Electrical
Revenue, Major Customer [Line Items]
Net sales	15,182	13,861
Other
Revenue, Major Customer [Line Items]
Net sales	9,998	10,392
United States and Puerto Rico
Revenue, Major Customer [Line Items]
Net sales	77,197	75,354
China
Revenue, Major Customer [Line Items]
Net sales	15,920	8,849
Brazil
Revenue, Major Customer [Line Items]
Net sales	9,860	8,713
Mexico
Revenue, Major Customer [Line Items]
Net sales	8,412	6,979
Germany
Revenue, Major Customer [Line Items]
Net sales	1,931	2,189
Poland
Revenue, Major Customer [Line Items]
Net sales	1,184	1,763
Other
Revenue, Major Customer [Line Items]
Net sales	12,300	12,366
Operating Segments | Mobile Solutions
Revenue, Major Customer [Line Items]
Net sales	77,776	69,884
Operating Segments | Mobile Solutions | Automotive
Revenue, Major Customer [Line Items]
Net sales	50,144	49,074
Operating Segments | Mobile Solutions | General Industrial
Revenue, Major Customer [Line Items]
Net sales	24,310	17,979
Operating Segments | Mobile Solutions | Electrical
Revenue, Major Customer [Line Items]
Net sales	0	0
Operating Segments | Mobile Solutions | Other
Revenue, Major Customer [Line Items]
Net sales	3,322	2,831
Operating Segments | Mobile Solutions | United States and Puerto Rico
Revenue, Major Customer [Line Items]
Net sales	37,438	37,129
Operating Segments | Mobile Solutions | China
Revenue, Major Customer [Line Items]
Net sales	14,414	7,692
Operating Segments | Mobile Solutions | Brazil
Revenue, Major Customer [Line Items]
Net sales	9,668	8,583
Operating Segments | Mobile Solutions | Mexico
Revenue, Major Customer [Line Items]
Net sales	5,015	4,836
Operating Segments | Mobile Solutions | Germany
Revenue, Major Customer [Line Items]
Net sales	1,767	2,150
Operating Segments | Mobile Solutions | Poland
Revenue, Major Customer [Line Items]
Net sales	1,180	1,758
Operating Segments | Mobile Solutions | Other
Revenue, Major Customer [Line Items]
Net sales	8,294	7,736
Operating Segments | Power Solutions
Revenue, Major Customer [Line Items]
Net sales	49,075	46,401
Operating Segments | Power Solutions | Automotive
Revenue, Major Customer [Line Items]
Net sales	13,460	12,364
Operating Segments | Power Solutions | General Industrial
Revenue, Major Customer [Line Items]
Net sales	13,710	12,543
Operating Segments | Power Solutions | Electrical
Revenue, Major Customer [Line Items]
Net sales	15,182	13,861
Operating Segments | Power Solutions | Other
Revenue, Major Customer [Line Items]
Net sales	6,723	7,633
Operating Segments | Power Solutions | United States and Puerto Rico
Revenue, Major Customer [Line Items]
Net sales	39,806	38,297
Operating Segments | Power Solutions | China
Revenue, Major Customer [Line Items]
Net sales	1,506	1,157
Operating Segments | Power Solutions | Brazil
Revenue, Major Customer [Line Items]
Net sales	192	130
Operating Segments | Power Solutions | Mexico
Revenue, Major Customer [Line Items]
Net sales	3,397	2,143
Operating Segments | Power Solutions | Germany
Revenue, Major Customer [Line Items]
Net sales	164	39
Operating Segments | Power Solutions | Poland
Revenue, Major Customer [Line Items]
Net sales	4	5
Operating Segments | Power Solutions | Other
Revenue, Major Customer [Line Items]
Net sales	4,006	4,630
Intersegment Sales Eliminations
Revenue, Major Customer [Line Items]
Net sales	(47)	(72)
Intersegment Sales Eliminations | Automotive
Revenue, Major Customer [Line Items]
Net sales
Intersegment Sales Eliminations | General Industrial
Revenue, Major Customer [Line Items]
Net sales
Intersegment Sales Eliminations | Electrical
Revenue, Major Customer [Line Items]
Net sales
Intersegment Sales Eliminations | Other
Revenue, Major Customer [Line Items]
Net sales	(47)	(72)
Intersegment Sales Eliminations | United States and Puerto Rico
Revenue, Major Customer [Line Items]
Net sales	(47)	(72)
Intersegment Sales Eliminations | China
Revenue, Major Customer [Line Items]
Net sales	0	0
Intersegment Sales Eliminations | Brazil
Revenue, Major Customer [Line Items]
Net sales	0	0
Intersegment Sales Eliminations | Mexico
Revenue, Major Customer [Line Items]
Net sales	0	0
Intersegment Sales Eliminations | Germany
Revenue, Major Customer [Line Items]
Net sales	0	0
Intersegment Sales Eliminations | Poland
Revenue, Major Customer [Line Items]
Net sales	0	0
Intersegment Sales Eliminations | Other
Revenue, Major Customer [Line Items]
Net sales	$ 0	$ 0

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue, Major Customer [Line Items]
Net sales	$ 126,804	$ 116,213
Major Customer
Revenue, Major Customer [Line Items]
Net sales	$ 13,100	$ 11,100
Major Customer | Customer Concentration Risk | Sales Revenue, Net
Revenue, Major Customer [Line Items]
Concentration risk, percentage	10.00%	10.00%

Shared-Based Compensation - Add

Shared-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 886	$ 1,296
Discontinued Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		200
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 548	$ 892
Stock units issued (in shares)	425
Fair value assumptions, exercise price (in dollars per share)	$ 6.79
Total grant-date fair value of restricted stock, vested	$ 2,700
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	142
Award performance period	36 months
Percentage of shares issuable based on threshold performance	50.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued (in shares)	172
Percentage of shares issuable based on target performance	100.00%
Employees | Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Non-executive Directors | Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	1 year

Shared-Based Compensation - Com

Shared-Based Compensation - Components of Share-Based Compensation Expense by Type of Award (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 886	$ 1,296
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	89	181
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	548	892
Performance share units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 249	$ 223

Shared-Based Compensation - Rec

Shared-Based Compensation - Reconciliation of Option Activity (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Number of Options (in thousands)
Beginning balance (in shares) | shares	871
Forfeitures or expired (in shares) | shares	(24)
Ending balance (in shares) | shares	847
Options exercisable (in shares) | shares	751
Weighted- Average Exercise Price (per share)
Beginning balance (in dollars per share) | $ / shares	$ 12.41
Forfeitures or expired (in dollars per share) | $ / shares	13.41
Ending balance (in dollars per share) | $ / shares	12.38
Options exercisable (in dollars per share) | $ / shares	$ 12.83
Weighted- Average Remaining Contractual Term
Outstanding	3 years 8 months 12 days
Options exercisable	3 years
Aggregate Intrinsic Value
Outstanding | $	$ 0
Options exercisable | $	$ 0

Shared-Based Compensation - R_2

Shared-Based Compensation - Reconciliation of Restricted Stock Option Activity (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Restricted stock
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	385
Nonvested restricted shares, granted (in shares) | shares	425
Nonvested restricted shares, vested (in shares) | shares	(284)
Nonvested restricted shares, forfeited (in shares) | shares	(12)
Nonvested restricted shares, ending balance (in shares) | shares	514
Weighted Average Grant-Date Fair Value (per share)
Beginning balance (in dollars per share) | $ / shares	$ 9.42
Granted (in dollars per share) | $ / shares	6.79
Vested (in dollars per share) | $ / shares	9.50
Forfeited (in dollars per share) | $ / shares	7.76
Ending balance (in dollars per share) | $ / shares	$ 7.24
TSR Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	138
Nonvested restricted shares, granted (in shares) | shares	142
Nonvested restricted shares, ending balance (in shares) | shares	280
Weighted Average Grant-Date Fair Value (per share)
Beginning balance (in dollars per share) | $ / shares	$ 10.58
Granted (in dollars per share) | $ / shares	8.58
Ending balance (in dollars per share) | $ / shares	$ 9.56
ROIC Awards
Nonvested Shares (in thousands)
Nonvested restricted shares, beginning balance (in shares) | shares	160
Nonvested restricted shares, granted (in shares) | shares	172
Nonvested restricted shares, ending balance (in shares) | shares	332
Weighted Average Grant-Date Fair Value (per share)
Beginning balance (in dollars per share) | $ / shares	$ 9.13
Granted (in dollars per share) | $ / shares	7.20
Ending balance (in dollars per share) | $ / shares	$ 8.13

Shared-Based Compensation - Sch

Shared-Based Compensation - Schedule of Performance Based Awards Goals with Respect to TSR and ROIC (Detail)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	35.00%
Target performance, percentage	50.00%
Maximum performance, percentage	75.00%
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold performance, percentage	6.30%	6.70%
Target performance, percentage	7.00%	7.90%
Maximum performance, percentage	8.60%	8.70%

Shared-Based Compensation - Sum

Shared-Based Compensation - Summary of Number of Awards Granted and Grand Date Fair Value (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2021$ / sharesshares
TSR Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-option equity instruments, outstanding (in shares) | shares	142
Grant Date Fair Value (in dollars per share) | $ / shares	$ 8.58
ROIC Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-option equity instruments, outstanding (in shares) | shares	172
Grant Date Fair Value (in dollars per share) | $ / shares	$ 7.20

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 254,152	$ 353,277
OCI before reclassifications, net of tax	(3,347)	(25,551)
Net other comprehensive income (loss), net of tax	(496)	(24,499)
Ending balance	234,755	78,902
Loss on Interest Rate Swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, net of tax	2,851
Interest Expense
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, net of tax		1,052
Accumulated other comprehensive income (loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(33,732)	(44,554)
Ending balance	(34,228)	(69,053)
Foreign Currency Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(30,881)	(35,159)
OCI before reclassifications and tax	(3,347)	(14,342)
Net other comprehensive income (loss), before tax	(3,347)	(14,342)
Ending balance	(34,228)	(49,501)
Foreign Currency Translation | Loss on Interest Rate Swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, before tax	0
Foreign Currency Translation | Interest Expense
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, before tax		0
Interest rate swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3,712)	(12,234)
OCI before reclassifications and tax	0	(14,599)
Net other comprehensive income (loss), before tax	3,712	(13,229)
Ending balance	0	(25,463)
Interest rate swap | Loss on Interest Rate Swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, before tax	3,712
Interest rate swap | Interest Expense
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, before tax		1,370
Income taxes
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	861	2,839
OCI before reclassifications, tax	0	3,390
Net other comprehensive income (loss), tax	(861)	3,072
Ending balance	0	5,911
Income taxes | Loss on Interest Rate Swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, tax	$ (861)
Income taxes | Interest Expense
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Amounts reclassified from AOCI, tax		$ (318)

Net Income (Loss) Per Common _3

Net Income (Loss) Per Common Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Loss from continuing operations	$ (4,913)	$ (108,077)
Less: Preferred stock cumulative dividends and deemed dividends	(14,529)	(2,951)
Numerator for basic income (loss) from continuing operations per common share	(19,442)	(111,028)
Numerator for diluted income (loss) from continuing operations per common share	(19,442)	(111,028)
Loss from discontinued operations, net of tax (Note 2)	0	(140,114)
Numerator for basic undistributed net loss per common share	(19,442)	(251,142)
Numerator for diluted undistributed net loss per common share	$ (19,442)	$ (251,142)
Weighted average common shares outstanding, basic (in shares)	42,461	42,111
Weighted average common shares outstanding, diluted (in shares)	42,461	42,111
Weighted average warrants outstanding, basic (in shares)	211	0
Weighted average warrants outstanding, diluted (in shares)	211	0
Weighted average common shares outstanding, basic (in shares)	42,672	42,111
Weighted average common shares outstanding, diluted (in shares)	42,672	42,111
Basic loss from continuing operations per common share (in dollars per share)	$ (0.46)	$ (2.64)
Basic loss from discontinuing operations per common share (in dollars per share)	0	(3.32)
Basic net loss per share (in dollars per share)	(0.46)	(5.96)
Diluted loss from continuing operations per common share (in dollars per share)	(0.46)	(2.64)
Diluted loss from discontinuing operations per common share (in dollars per share)	0	(3.32)
Diluted net loss per share (in dollars per share)	(0.46)	(5.96)
Cash dividends declared per share (in dollars per share)	$ 0	$ 0

Net Income (Loss) Per Common _4

Net Income (Loss) Per Common Share - Antidilutive Securities Excluded from Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	2,347	28,672
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	847	897
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	1,500	1,500
Preferred Stock, as-converted
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	26,275

Net Income (Loss) Per Common _5

Net Income (Loss) Per Common Share - Additional Information (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, minimum price range (in dollars per share)	$ 7.93	$ 7.93
Anti dilutive securities excluded from computation of earnings per share, maximum price range (in dollars per share)	$ 25.16	$ 25.16

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Mar. 22, 2021	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants term		4 years 3 months 18 days	4 years 3 months 18 days		2 years 4 months 24 days
Cash settlements for interest rate swaps			$ 15,420	$ 0
International lines of credit and other loans		$ 12,500	$ 12,500		$ 14,400
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change-in-control put feature			1.00%
Preferred stock remaining in future periods, probability percentage					2.00%
Probability percentage of leverage ratio put being exercisable					1.00%
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change-in-control put feature			10.00%
Preferred stock remaining in future periods, probability percentage					3.00%
Probability percentage of leverage ratio put being exercisable					10.00%
Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, fixed interest rate					2.4575%
Cash settlements for interest rate swaps	$ 13,700
Series B Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Dividends withholdings net cash distribution		$ 3,000
Dividends withholdings offset from purchasers upon redemption			$ 1,000
Class of warrant or right, exercise price of warrants or rights (in dollars per share)					$ 12
Adjusted exercise price of warrants or rights (in dollars per share)		$ 11.49	$ 11.49
Series D Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.01
Liquidation preference	140.00%

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities Measure at Fair Value Preferred Stock (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	$ 13,414	$ 0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Noncurrent Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	13,414	0
Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Other Observable Inputs (Level 2) | Other Current Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Other Observable Inputs (Level 2) | Other Noncurrent Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	1,370	3,117
Significant Unobservable Inputs (Level 3) | Other Current Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	0	2,453
Significant Unobservable Inputs (Level 3) | Other Noncurrent Liabilities
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, fair value, gross liability	$ 1,370	$ 664

Fair Value Measurements - Roll

Fair Value Measurements - Roll Forward of Preferred Stock Derivative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 3,117
Issuances	15,121
Change in fair value	(449)
Settlements	(3,005)
Ending balance	$ 14,784

Fair Value Measurements - Effec

Fair Value Measurements - Effect of Interest Rate Swap (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Derivative [Line Items]
Interest expense	$ 2,024	$ 3,807
Derivative payments on interest rate swap	1,717	0
Loss on interest rate swap	2,033	0
Interest Rate Swap
Derivative [Line Items]
Interest expense	$ 0	$ 1,370

Fair Value Measurements - Inter

Fair Value Measurements - Interest Rate Swap (Details) - Fair Value, Measurements, Recurring - Interest Rate Swap $ in Thousands	Dec. 31, 2020USD ($)
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	$ 0
Derivative liability - other non-current liabilities	0
Total	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	11,022
Derivative liability - other non-current liabilities	4,357
Total	15,379
Significant Unobservable Inputs (Level 3)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Derivative liability - other current liabilities	0
Derivative liability - other non-current liabilities	0
Total	$ 0